$HBB

HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES QUARTERLY DIVIDEND

Hamilton Beach Brands Holding Company (HBB) declared a quarterly cash dividend of $0.125 per share, payable September 15, 2026, to shareholders of record on September 1, 2026. The dividend applies to both Class A and Class B Common Stock.

Original reporting
Published Aug 19, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES QUARTERLY DIVIDEND — source image
Decision brief

The 30-second read

$HBBNeutralLow
01

Why it matters

The declared dividend is a routine corporate action, offering a modest cash return to shareholders without altering the company's growth outlook.

02

Market read

A standard dividend announcement for a mid‑cap consumer‑goods firm; limited trading relevance.

03

What to watch

Potential tax considerations for dividend‑receivers and upcoming earnings guidance.

Relevance 4/10Novelty 3/10Timing: announced Aug 19 2026

Background

Hamilton Beach Brands Holding Company (NYSE:HBB) is a maker of small household appliances and commercial equipment.

Company-level read

Ticker impact

$HBBNeutralHigh confidence
Context

Board declared a quarterly cash dividend of $0.125 per share payable Sep 15, 2026.

Expected impact

minor upside for dividend‑seeking investors, negligible for broader market.

Evidence & confidence

Small cash payout on a mature consumer‑goods company; typical corporate action.

Market effects

Minimal impact on small‑appliance sector; reinforces dividend‑yield narrative.

US‑listed consumer‑goods space sees slight dividend‑yield boost.

Limited; only relevant to investors tracking dividend income.

Counterpoint

Dividend may signal limited growth opportunities; investors could prefer capital‑return alternatives.

Key entities

  • Hamilton Beach Brands Holding Company

    Issuer of the dividend.

Related articles

$HBBMedAI 8/10

Hamilton Beach (HBB) Q2 2026 Earnings Call Transcript

Hamilton Beach Brands Holding (HBB) reported Q2 2026 revenue of $142.6M, up 11.6% year over year, and net income of $33.7M ($2.49 diluted EPS). Management attributed higher margins and operating profit to a one-time IEEPA tariff refund. The company raised 2026 gross margin and operating profit guidance and projected $35M to $45M operating cash flow less investing.

$HBBMed

Hamilton Beach Brands Q2 Earnings Call Highlights

Hamilton Beach Brands (HBB) reported Q2 gross margin of 26.1% excluding tariff-related benefits, and said it expects 2026 revenue growth in the mid-single-digit range. Management forecast full-year gross margin to improve modestly and operating profit to decline by a high-single-digit percentage. Operating cash flow is expected at $35M to $45M. HBB ended with net cash of $51.5M.

$HBBHigh

Hamilton Beach Brands Holding Co (HBB): Results of Operations and Financial Condition

Hamilton Beach Brands Holding Co (HBB) filed an SEC Form 8-K — Results of Operations and Financial Condition. CONTACT: Brendon Frey Brendon.frey@icrinc.com HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES SECOND QUARTER RESULTS Second Quarter Revenue Increased 11.6% to $142.6 Million Reiterates 2026 Revenue Outlook, Raises Gross Margin and Operating Profit Outlook Glen Allen, Virginia - H

$ACVAMed

Robust Results and Share Repurchase Authorization Boosted ACV Auctions (ACVA)

Meridian Hedged Equity Fund highlighted ACV Auctions (ACVA) in its Q2 2026 investor letter, noting its record Q1 results, $100M share repurchase plan, and AI-driven solutions. ACVA's stock declined 10.19% over the past month and 43.27% over the past year, with a market cap of $1.14B. The fund holds ACVA, citing its market share gains and strong fundamentals.

$NTLAMedAI 9/10

Intellia Secures Up To $400 Mln Non-Dilutive Debt Facility From OrbiMed

Intellia Therapeutics (NTLA) secured a $400 million debt facility from OrbiMed, with $75 million funded at closing and $225 million tied to milestones for lonvo-z, a CRISPR gene-editing therapy. The facility provides financial flexibility for lonvo-z's development and potential U.S. launch for hereditary angioedema (HAE). NTLA shares are up 0.63% at $12.76.